BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 6, 2016, 8:05 PM UTC
BusinessPreclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXApr 20, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent DevelopmentsBy Nasdaq OMXMar 9, 2016, 1:00 PM UTC
BusinessPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016By Nasdaq OMXMar 3, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
